<DOC>
	<DOC>NCT00089713</DOC>
	<brief_summary>This study comprises a 3- to 6-week hydrochlorothiazide run in phase, followed by a 12 week double-blind treatment phase, followed by a 2 week single-blind follow-up hydrochlorothiazide treatment phase. The combined total duration of patient participation is approximately 17-20 weeks. Four double-blind treatment groups approximately equal in size (98) will comprise the study population: placebo or various alagebrium dose groups (10, 50, or 150 mg/day).</brief_summary>
	<brief_title>Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Men or women at least 45 years of age with uncontrolled systolic hypertension measured by office cuff and by an ambulatory blood pressure monitoring device Willingness to be taken off any current antihypertensive treatment to be placed on hydrochlorothiazide in combination with study medication. Any significant history, systemic illnesses, or medical condition(s) that could lead to difficulty complying with the protocol or that could confound interpretation of the data.</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>antihypertensive agents/therapeutic use</keyword>
	<keyword>hypertension/drug therapy</keyword>
	<keyword>blood pressure</keyword>
</DOC>